
Viatris Inc company profile
$20.82+0.73%Close 13 Nov 2026
About Viatris Inc
Viatris is a global healthcare company that supplies generic medicines, complex products, branded and iconic brands, and an expanding portfolio of innovative medicines. It sells to retail and pharmacy establishments, wholesalers, governments, institutions, physicians and other customers across more than 165 countries and territories. The Company operates 27 manufacturing, packaging and distribution sites, with manufacturing in locations including the U.S., Puerto Rico, Singapore, India, Australia, China and certain EU countries. It reports through four segments: Developed Markets, Emerging Markets, JANZ and Greater China. Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India. Its portfolio spans more than 10 major therapeutic areas, and it has more than 1,400 approved molecules.
A summary of the business section of the company's latest annual report, filed 26 Feb 2026.
Company facts
| Ticker | VTRS · Nasdaq |
|---|
| Sector | Pharmaceuticals |
|---|
| Industry | Pharmaceuticals |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 1792044 |
|---|
| Latest annual report | 10-K, filed 26 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Scott A. Smith | Chief Executive Officer · Director | 1.3M · < 1% | Shares withheld for tax, 6 Mar 2026 |
|---|
| Brian Roman | Chief Legal Officer | 328K · < 1% | Shares withheld for tax, 4 Mar 2025 |
|---|
| Melina Higgins | Director | 220K · < 1% | Option exercise, 6 Mar 2026 |
|---|
| Andrew Enrietti | See Remarks | 220K · < 1% | Option exercise, 15 Aug 2026 |
|---|
| Mark Parrish | Director | 165K · < 1% | Option exercise, 6 Mar 2026 |
|---|
| James M. Kilts | Director | 161K · < 1% | Option exercise, 6 Mar 2026 |
|---|
| Richard Mark | Director | 116K · < 1% | Option exercise, 6 Mar 2026 |
|---|
| W. Don Cornwell | Director | 112K · < 1% | Option exercise, 6 Mar 2026 |
|---|
| JoEllen Lyons Dillon | Director | 103K · < 1% | Option exercise, 6 Mar 2026 |
|---|
| Corinne Le Goff | Chief Commercial Officer | 83.2K · < 1% | Shares withheld for tax, 15 Apr 2026 |
|---|
| Leo Groothuis | Director | 63.4K · < 1% | Option exercise, 6 Mar 2026 |
|---|
| Elisha Finney | Director | 62.7K · < 1% | Option exercise, 6 Mar 2026 |
|---|
| Michael Severino, M.D. | Director | 26.0K · < 1% | Option exercise, 6 Mar 2026 |
|---|
| David Simmons | Director | 24.5K · < 1% | Option exercise, 6 Mar 2026 |
|---|
| Campbell Paul | See Remarks | — | Sale under a 10b5-1 plan, 25 Jun 2026 |
|---|
| Mistras Theodora | Chief Financial Officer | — | Shares withheld for tax, 6 Mar 2026 |
|---|
| Vivaldi Coelho Rogerio | Director | — | Option exercise, 6 Mar 2026 |
|---|
| DAMELIO FRANK A | Director | — | Option exercise, 6 Mar 2026 |
|---|
| KORMAN HARRY | Director | — | Option exercise, 4 Mar 2025 |
|---|
| Malik Rajiv | Director | — | Option exercise, 4 Mar 2025 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
VTRS in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.